Search Results for: Global Cancer Vaccine Market to
Global Cancer Vaccine Market to Reach $4.3 Billion in 2019 January 13, 2015BCC Research recently announced in its new report, Cancer Vaccines: Technologies and Global Markets, the global market for cancer vaccines...
Bavarian Nordic Initiates Phase 3 Trial of Vaccine June 20, 2019Bavarian Nordic A/S recently announced the initiation of a pivotal Phase 3 trial of the freeze-dried formulation of MVA-BN smallpox...
CHECKPOINT INHIBITORS – Novel Targets & Global Markets April 29, 2019
Laurie L. Sullivan and Cheryl L. Barton, PhD, say as manufacturers expand the clinical utility and healthcare professionals become more familiar with their efficacy and safety profiles, the checkpoint inhibitor market will continue to expand, becoming the cornerstone of many cancer treatment regimens.
EXECUTIVE INTERVIEW – MilliporeSigma: Accelerating the Development & Manufacture of Gene Therapies, Immunotherapies & Viral Vaccines April 2, 2018
Dave Backer, Head of Virus & Gene Therapy Strategic Initiatives at MilliporeSigma, talks about his company’s expanding GMP capacity to speed development and manufacture of gene therapies, immunotherapies, and viral vaccines.
GLOBAL REPORT – 2017 Global Drug Delivery & Formulation Report: Part 1, a Global Review March 15, 2018
In part 1 of this 4-part series, PharmaCircle in collaboration with Drug Development & Delivery, focuses on the macro aspects of the 2017 product approvals.
Immunovaccine & Leidos Expand Collaboration November 27, 2017Immunovaccine Inc. recently announced it is expanding its collaboration with Leidos to develop preventative, peptide-based malaria vaccine candidates. The US...
Immuno-Oncology Looks Set to Become Fifth Pillar of Cancer Treatment September 18, 2017Immuno-Oncology (IO) looks set to become the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and other targeted treatments...
EXECUTIVE INTERVIEW – Viral Gene: Protein-Targeting Cancer Vaccine Could Boost Survival Rates January 13, 2017
Harry A. Arena, MBA, President & CEO of TDT, Chris Kim, President & General Counsel, Viral Gene, Inc., and Dr. Scott Waldman, Professor & Chair of Sidney Kimmel Medical College’s Department of Pharmacology & Experimental Therapeutics at Thomas Jefferson University, discuss the unique characteristics of the vaccine, the patients who will benefit the most, and how a research team captured the attention of investors.
Cancer Vaccines Market Will Soar to $7.5 Billion by 2022 November 17, 2016The cancer vaccines market is set to almost triple from $2.5 billion in 2015 to $7.5 billion by 2022, representing...
BioSun & ARTES Announce Co-Development Agreement for HPV Vaccine November 8, 2016BioSun Pharmed and ARTES Biotechnology recently announced they will join forces for the development and manufacturing of a HPV (human...
PROTEIN THERAPEUTICS MARKET – Technology Advances Spur Market Growth of Protein Therapies November 7, 2016
Laurie L. Sullivan and Shalini S. Dewan, BCC Research Analysts, believe with the advent of genetic engineering and recombinant DNA technology, it is now possible to produce a wide variety of human proteins, and that these novel technologies have lifted the market for therapeutic proteins to new heights.
CELL CULTURE MARKET – 3D Cell Cultures: Next Generation & New Challenges November 19, 2015
Kevin James and Robert G. Hunter of BCC Research say significant growth within the biopharmaceuticals industry is spurring unprecedented innovation in and demand for cell culture products for the purposes of drug discovery and safety testing. While 2D cell cultures have been in laboratory use since the 1950s, the market for 3D cultures has witnessed spectacular growth throughout the past decade.